Financial Data and Key Metrics Changes - Quarterly revenue increased by 75.4% year over year to $255.7 million [5] - Genomics revenue reached $193.8 million, reflecting approximately 89% year over year growth [5] - Gross profit for the quarter was $155.2 million, representing 99.8% growth year over year [6] - Adjusted EBITDA improved to negative $16.2 million from negative $43.9 million year over year, an improvement of $27.8 million [6] - Full year 2025 revenue guidance increased to $1.25 billion, indicating about 80% year over year growth [7] Business Line Data and Key Metrics Changes - Oncology testing revenue grew by 31% year over year with approximately 20% volume growth [5] - Hereditary testing contributed $63.5 million in revenue, with unit growth of 23% [6] - Revenue from data and services totaled $61.9 million, marking about 43% year over year growth, led by insights or data licensing business which grew by 58% [6] Market Data and Key Metrics Changes - The company reported a total remaining contract value exceeding $1 billion as of April 30 [9] - The insights business is growing rapidly, with a significant contract with AstraZeneca pushing total remaining contract value over $1 billion for the first time [50] Company Strategy and Development Direction - The company is focused on building the world's largest foundation model in oncology through a three-year $200 million data and modeling license agreement with AstraZeneca and Pathos [8][9] - The strategic partnership aims to enhance drug discovery efforts and advance diagnostic and data products [9][10] - The company is committed to making precision medicine a reality by leveraging AI and large datasets to improve patient outcomes [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's performance, highlighting strong revenue and gross profit growth while managing costs effectively [5][8] - The management noted that the excitement from other pharmaceutical companies regarding the Pathos deal has exceeded expectations, indicating potential for future collaborations [15][16] - The company is cautious about growth rates in the hereditary testing business but sees long-term potential for high growth [24][26] Other Important Information - The company is investing in AI technology and data to enhance its diagnostic capabilities and maintain competitive advantages [39][40] - The acquisition of Deep Six is expected to enhance the company's data connectivity and analytics capabilities [28][32] Q&A Session Summary Question: Follow-up on the Pathos deal and its implications for future collaborations - Management noted significant interest from other pharmaceutical companies following the Pathos deal, with ongoing discussions about similar agreements [15][16] Question: Insights on the Hereditary business performance - Management indicated that the hereditary testing business is performing better than expected, with potential for continued strong growth [24][26] Question: Details on the Deep Six acquisition and its capabilities - The acquisition is aimed at enhancing data connectivity and analytics, which are crucial for building comprehensive molecular datasets [28][32] Question: Impact of macroeconomic factors on TCV and potential cancellations - Management acknowledged some impact on biotech funding but emphasized that relationships with large pharma companies remain strong and committed [70][71] Question: Update on MRD assay performance and expectations - Management reported strong demand for both tumor naive and tumor informed assays, with positive long-term positioning in the MRD space [75][79]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $17.8 million, up from $15.8 million in Q1 2024, representing a year-over-year growth of 13% [31] - On a constant currency basis, revenue growth was 15%, with foreign exchange headwinds negatively impacting reported revenue by approximately $0.4 million [31] - Adjusted EBITDA loss improved by 24% year-over-year to $9.8 million in Q1 2025 [35] - Adjusted gross margin reached a record high of 75.7%, up from 70.6% in Q1 2024 [33] Business Line Data and Key Metrics Changes - Core genomic customers increased to 490 as of March 31, 2025, up from 463 in the prior year [31] - The company implemented 33 new customers in Q1 2025, compared to an average of 23 per quarter in 2024 [8][47] - Hematology-oncology (HemOnc) volumes grew 34% year-over-year in Q1 2025, with over 180 HemOnc customers globally [20] Market Data and Key Metrics Changes - Revenue and analysis volume from U.S. core genomic customers grew over 30% year-over-year [9] - UK analysis volume grew over 60% year-over-year, with UK revenue up approximately 80% [19] - In Asia Pacific, North America and Asia Pacific outperformed with 3240% year-over-year volume growth [18] Company Strategy and Development Direction - The company aims to capitalize on new customer signings by expediting implementation times and expanding across those accounts [8] - Focus areas for growth in 2025 include the U.S. market, new applications like MSK Access and MSK Impact, and partnerships with biopharma [10][11] - The company is positioned to leverage its scalable cloud-based platform to support medical innovations and expand its offerings in liquid biopsy and solid tumor applications [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential, citing a strong start to 2025 and a solid pipeline of new business [43] - The company reaffirmed its full-year revenue guidance for 2025 of $70 million to $76 million, representing 10% to 17% growth [37] - Management noted that while Q1 results were strong, they expect the year to be back half weighted due to new business coming online [37][93] Other Important Information - The company finished Q1 2025 with cash and cash equivalents of approximately $68.5 million, with access to an additional $35 million through a financing line [36][88] - Total cash burn improved to $11.7 million in Q1 2025, down from $19.5 million in the prior year [36] Q&A Session Summary Question: Actions taken to accelerate implementation times - Management highlighted that they implemented 33 new customers in Q1 2025, up from an average of 23 in 2024, due to scaling up team capabilities and creating tooling and automation to speed up processes [47][49] Question: Average contract value increase and enterprise sales - Management confirmed that 58% of customers are using two or more applications, indicating room for expansion. The increase in average contract value is attributed to more complex solutions and enterprise-level sales [53][55] Question: Sustainability of gross margins above 75% - Management acknowledged that while Q1 gross margins were higher than expected due to a favorable mix, they anticipate continued year-over-year improvement but not at the same level in subsequent quarters [62][63] Question: Biopharma side opportunities and guidance - Management indicated that while they expect the biopharma segment to be flat in 2025, they are seeing good momentum and opportunities in the pipeline, particularly in companion diagnostics [68] Question: Impact of macro environment on capital investments - Management noted that while there is a trend of constraints on capital investments, their model operates on an OpEx basis, which may present opportunities for growth as labs seek to avoid large capital expenditures [71][73]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $17.8 million, up from $15.8 million in Q1 2024, representing a year-over-year growth of 13% [32] - On a constant currency basis, revenue growth was 15%, with foreign exchange headwinds negatively impacting reported revenue by approximately $0.4 million [32] - Adjusted EBITDA loss improved by 24% year-over-year, reaching $9.8 million in Q1 2025 compared to $12.9 million in Q1 2024 [36] - Adjusted gross margin reached a record high of 75.7%, up from 70.6% in the prior year [34] Business Line Data and Key Metrics Changes - Core genomic customers increased to 490 as of March 31, 2025, up from 463 in the prior year [32] - The company implemented 33 new customers in Q1 2025, compared to an average of 23 per quarter in 2024 [8][32] - Hematology-oncology (HemOnc) volumes grew 34% year-over-year in Q1 2025, with over 180 HemOnc customers globally [21] Market Data and Key Metrics Changes - Revenue and analysis volume from U.S. core genomic customers grew over 30% year-over-year [9] - UK analysis volume grew over 60% year-over-year, with UK revenue up approximately 80% [20] - North America and Asia Pacific outperformed with 3240% year-over-year volume growth respectively [19] Company Strategy and Development Direction - The company aims to capitalize on new customer signings by expediting implementation times and expanding across those accounts over time [8] - Focus areas for growth in 2025 include the U.S. market, new applications like MSK Access and MSK Impact, and partnerships with biopharma [9][11] - The company is positioned to leverage its scalable cloud-based platform to support medical innovations and drive future growth [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential, citing the increasing demand for data-driven medicine and the company's unique AI capabilities [44] - The company reaffirmed its full-year revenue guidance for 2025 of $70 million to $76 million, representing 10% to 17% growth [38] - Management noted that while Q1 results were strong, they expect the year to be back-half weighted due to the timing of new business coming online [38][94] Other Important Information - The company finished Q1 2025 with approximately $68.5 million in cash and cash equivalents, plus access to an additional $35 million in capital [37] - The company is focused on maintaining operational efficiencies while continuing to invest in high ROI projects [36] Q&A Session Summary Question: Actions taken to accelerate implementation times - Management highlighted that they have scaled up team capabilities, created tooling and automation, and increased headcount in wet lab and field application scientists to speed up the implementation process [48][50] Question: Average contract value increase and enterprise sales - Management confirmed that 58% of customers are using two or more applications, indicating room for expansion. They noted that enterprise sales involve signing for a majority of applications, which is driving the increase in average contract value [55][56] Question: Sustainability of gross margins above 75% - Management acknowledged that while Q1 gross margins were higher than expected due to a favorable mix, they still anticipate year-over-year improvements in gross margins moving forward [66] Question: Biopharma side opportunities and guidance - Management indicated that while they expect the biopharma segment to be flat in 2025, they are seeing good momentum and opportunities in the pipeline, particularly in companion diagnostics and sponsored testing [70] Question: Balance sheet sufficiency for adjusted EBITDA breakeven target - Management confirmed that with over $100 million in available liquidity, they are well-positioned to reach their adjusted EBITDA breakeven target by 2027 [90]

Weave Overview Q1 2025 NYSE : WEAV MAY 2025 1 Safe Harbor Statement This presentation has been prepared by Weave Communications, Inc. ("Weave", "we", "us", or "our") for informational purposes only and not for any other purpose. This presentation contains "forward-looking statements" within the Private Securities Litigation Reform Act of 1995 that are based on our management's current expectations and projections about future events and financial trends that we believe may affect our financial condition, re ...

Financial Data and Key Metrics Changes - eHealth reported a record high revenue of $315.2 million for Q4 2024, representing a 27% increase year-over-year, and a 33% increase when excluding net adjustment revenue [43] - GAAP net income for Q4 2024 increased by 87% to $97.5 million, up from $52.2 million [43] - Adjusted EBITDA for Q4 grew 74% to $121.3 million, with an adjusted EBITDA margin of 38% [44][50] - Full year 2024 revenue reached $532.4 million, an 18% increase, with adjusted EBITDA of $69.3 million, up from $14.1 million in 2023 [51][52] Business Line Data and Key Metrics Changes - Medicare segment revenue grew 31% to $305.8 million in Q4 2024, with total Medicare submissions increasing by 38% [44][45] - The Agency fulfillment model saw submissions rise by 49%, reflecting consumer preference for platforms with broad plan offerings [45] - The E&I segment revenue decreased by 33% to $9.4 million in Q4, with a gross profit of $4 million [47] Market Data and Key Metrics Changes - The Medicare Advantage lifetime value (LTV) increased by 2% to $1,174, with an LTV to customer acquisition cost (CAC) ratio of 2x, exceeding the target of 1.7x [46] - The company observed unprecedented disruption in the Medicare Advantage market, leading to increased consumer demand and a record high switching rate of 23% during the annual enrollment period [11][74] Company Strategy and Development Direction - eHealth aims to expand brand recognition beyond core Medicare products and enhance retention strategies [36][80] - The company plans to invest in AI and digital technology to improve service delivery and operational efficiency [25][37] - Strategic priorities include optimizing telesales operations and diversifying revenue streams through targeted investments in Medicare Supplement and ancillary products [35][61] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the fluid Medicare market and anticipates continued consumer demand [29][30] - The regulatory environment is expected to improve over the next four years, which could positively impact the Medicare Advantage sector [30] - Guidance for 2025 indicates a range of $510 million to $550 million in revenue, with expectations for adjusted EBITDA to decline relative to 2024 due to a more measured approach [57][63] Other Important Information - The company successfully navigated the Medicare sector disruption, taking market share and scaling its business at attractive economics [28] - eHealth ended 2024 with $82.2 million in cash and equivalents, with expectations for a significant increase in cash balance by the end of Q1 2025 [53][55] Q&A Session Summary Question: Expectations for 2025 in light of regulatory changes and competitive landscape - Management characterized the outlook as pragmatic, noting the rapid changes in administration and potential impacts on Medicare Advantage [70][72] Question: Impact of D-SNP rules on enrollment and marketing strategy - Management acknowledged the anticipated shift in D-SNP opportunities to Q4 and the need to adjust marketing strategies accordingly [84] Question: Future of the Amplify platform and its growth potential - Management remains optimistic about Amplify's evolution and its ability to scale and improve margins as it matures [88][94] Question: Changes in commission payments by carriers and their impact - Management indicated that while commission suppression was more pronounced, eHealth's broad carrier portfolio allowed it to navigate these challenges effectively [117][120]